AnaptysBio Isn't a Biotech Anymore. It's a Royalty Ladder That Must Keep Climbing.

A company announcing it will appear at the H.C. Wainwright conference is not news. It means management has a flight booked and a slide deck ready. But the name on this particular release no longer means what the ticker used to. AnaptysBio (ANAB) spent a decade as a clinical-stage immunology shop burning cash on Phase 2 bets. Over the last year it has been rebuilt into something a free-cash-flow investor can actually evaluate: a lean royalty company collecting a rising stream of checks from GSK's cancer drug Jemperli, with minimal overhead and a stated plan to give cash back. The market caught on early, and the stock roughly quintupled off its low. So the useful question is not whether the turnaround is real. It is whether the cash ladder still climbs fast enough to carry a ~$1.6 billion valuation, and what would knock it off.

Clinical-stage biotech is off my turf — binary science bets you cannot check against a cash path. So the old Anaptys was not my story. The new one is a different animal, because on April 20, 2026 the company spun off its entire drug-development operation into a separate public company, First Tracks Biotherapeutics, distributing one share for every Anaptys share held. What stayed behind is a "virtual" royalty manager with two financial collaborations — Jemperli with GSK and imsidolimab with Vanda — roughly $140–145 million of net cash, and management targeting an EBIT margin above 95%. The headline promise is worth quoting because it defines the whole investment question. The company says it is now focused on "protecting and returning value of Jemperli and imsidolimab royalties to shareholders."

That is the architecture. The economics all come down to one drug. GSK reported Jemperli sales of $313 million in the first quarter of 2026, up more than 40% year over year, and £248 million in the second quarter, up 27%. GSK guides to greater than £2 billion in peak monotherapy sales. Anaptys's royalty from GSK is tiered — 8% of global net sales below $1 billion, then 12%, 20%, and 25% on the bands above it — and Jemperli crossed the $1 billion line during 2025, which triggered a one-time $75 million commercial milestone payable to Anaptys last year. In the March 2026 quarter Anaptys booked $24.7 million of Jemperli royalties, up 44% from a year earlier. Annualize that single print and you get roughly a $100 million royalty run-rate today. Management's stated goal, anchored to GSK's >$2.7 billion peak guidance: more than $390 million in annualized Jemperli royalties payable to Anaptys as early as 2029.

Now the detail that reframes everything. A large share of the early years of that stream is not Anaptys's anymore. In 2021 and 2024 the company took $300 million of upfront cash ($250 million and then $50 million) from Sagard Healthcare in exchange for the 8% tier of the Jemperli royalty below the $1 billion sales threshold, plus certain milestones. The deal is non-recourse and capped: it runs until Sagard has cumulatively received $600 million (or $675 million if it drags past March 31, 2031). Through the first quarter of this year Sagard had already accrued roughly $275 million of that payoff, and management expected the remaining ~$325 million to be cleared by the end of the second quarter of 2027. In plain terms, the near-term royalty waterfall has been pre-sold to pay for a payout the company already spent on its former drug business. The above-$1 billion tiers — the 12%, 20%, and 25% bands — stay with Anaptys, which is why the story is built on Jemperli surpassing $1 billion and then compounding from there. The upside is real, but it sits on the far side of a $600 million claim that eats the early years.

Concentration deserves a second paragraph because it is the risk. One drug, one payer, and that payer is currently in court with its licensor. Late last year GSK's Tesaro arm sued Anaptys for an alleged material breach of the Jemperli agreement, and Anaptys countersued over GSK's duty to pursue Jemperli's "optimal commercial return" — alleging, among other things, that GSK paired its antibody-drug conjugates with competing PD-1 drugs instead of Jemperli. Anaptys announced in late April that the Delaware Chancery Court dismissed Tesaro's claims. The commercial-effort case lives on, and it is an uncomfortable thing to have the single largest variable in your thesis controlled by a counterparty you are suing. There is a smaller second stream — imsidolimab for generalized pustular psoriasis, which Vanda licensed globally for a 10% royalty and an FDA decision date of December 12, 2026 — but Jemperli is the ballgame.

Here is where the market sits, and I will be honest about why it makes me company. Shares have already run from a $11.40 fifty-two-week low to a $72.36 high before settling near $55, up more than 300% over the trailing year. Sell-side consensus is a Strong Buy with a price target near $87, and AInvest's aggregate signal labels the stock a Buy. A $100 million buyback authorized in March runs until the end of this year — the first concrete test of the "returning value" promise. The first full quarter as a royalty-only company, reported this week, landed at a net loss of roughly $0.31 a share, and the stock fell on it anyway — it sits about a quarter below the high. That is tape pain. The discipline question is whether any business pain came with it.

The mathematical case, stripped of machinery — no DCF, just one ladder and one clock — looks like this. At ~$1.6 billion market cap you are paying roughly 16 times the current ~$100 million royalty run-rate, or under five times the $390 million target, for a stream that management says triples-plus within a few years. That multiple is fair if Jemperli keeps compounding the way GSK expects. It is expensive if growth slips, because the payout continues either way and the near-term cash belongs to Sagard.

So the story needs specific things to stay true. The proof point is the royalty check itself: Jemperli's quarterly growth staying in the ~25–40% year-over-year band, and the Sagard paydown clock clearing on schedule so the whole stream reattaches around 2027. The tripwire is the first real warning I already hold: second-quarter Jemperli was up 27% year over year but only about 7% sequentially, while the company's own paydown model assumes roughly 10% quarter-over-quarter growth. One slow quarter is not a broken thesis, but the whole construct depends on a single molecule accelerating against a fixed $600 million claim, and the model's own math only works if it does.

The setup I want is the one where shares keep sliding while the checks keep compounding — tape pain without business pain. We are not there yet; $1.6 billion and unanimous bullishness is the crowd already comfortable, not a reset. If the next few Jemperli prints show the acceleration holding and Sagard's accrual closing toward the cap while the price drifts lower, that gap is the entry that fits how I work. I can be wrong again — one cancer drug, one payor, one lawsuit, and a pre-sold first act are not a low-risk portfolio hold. But the article that matters is not the conference schedule. It is next quarter's royalty number.